On August 10, 3SBIO rose 5.18% in regular trading, trading at 18.91 HKD/share, with turnover of approximately HKD 114 million. The rally was driven by multiple catalysts including the upcoming board meeting and favorable broker coverage.

On August 7, the company announced that its board of directors will convene on August 20 to review and approve the unaudited interim results for the six months ended June 30, and to consider declaring an interim dividend. Market expectations for earnings delivery and dividend distribution have strengthened ahead of the meeting. Additionally, CMB International recently named 3SBIO as a top pick in the innovative drug sector, citing strong industry fundamentals.

The broader innovative drug sector continued its recovery trend, with REMEGEN rising 4.93% and AKESO gaining 4.30%, providing further support through sector-wide momentum. Earlier in June, the company's chairman increased his stake by 516,000 shares at HKD 15.25 per share, while the company itself repurchased approximately 8.52 million shares in June, signaling management confidence in the company's valuation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)